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Edited by Hans-Dieter KlenkAbstract HIV-1 viral protein R (Vpr) is one of the human
immunodeﬁciency virus type 1 encoded proteins that have
important roles in viral pathogenesis. However, no clinical drug
for AIDS therapy that targets Vpr has been developed. Here,
we have established a screening system to isolate Vpr inhibitors
using budding yeast cells. We puriﬁed a Vpr inhibitory com-
pound from fungal metabolites and identiﬁed it as fumagillin,
a chemical already known to be a potent inhibitor of angiogen-
esis. Fumagillin not only reversed the growth inhibitory activity
of Vpr in yeast and human cells, but also inhibited Vpr-depen-
dent viral gene expression upon the infection of human macro-
phages.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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cycle1. Introduction
Viral protein R (Vpr) is a 96 amino acid, 14 kD nucleo-
philic protein that is incorporated into mature virions of hu-
man immunodeﬁciency virus type 1 (HIV-1). Vpr aids eﬃcient
translocation of the proviral DNA into the nucleus and is re-
quired for the HIV-1 infection of non-dividing cells such as
macrophages [1–4]. Vpr is also involved in activation of viral
transcription, induction of cell cycle G2 arrest and apoptosis
of the host cells upon the HIV-1 infection (for recent reviews,
see [5–7]). Although speciﬁc roles of these Vpr activities in vir-
al pathogenesis and disease progression have not been eluci-
dated, the eﬀects of Vpr mutations found in AIDS patients
suggest that Vpr is an important cytotoxic component of
HIV-1 infection [8–10]. However, no Vpr targeted small
molecule that can be used for AIDS therapy has yet been
developed.
Fumagillin, a natural product of fungal origin, was discov-
ered to act as a potent inhibitor of angiogenesis [11]. A semi-Abbreviations: HIV-1, human immunodeﬁciency virus type 1; Vpr,
viral protein R; MetAP2, methionine aminopeptidases 2
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doi:10.1016/j.febslet.2006.04.007synthetic analog of fumagillin, TNP-470 (AGM-1470) is 50
times more active inhibitor of angiogenesis than its parent
compound [11]. Since these compounds are covalent inhibitors
selective for a protease, methionine aminopeptidases 2 (Me-
tAp2), MetAp2 had been considered for the responsible molec-
ular target for the inhibition of angiogenesis [12,13]. However,
since there are two reports contradicting each other about the
matter whether inhibition of angiogenesis by fumagillin is
dependent on the MetAP2 activity or not, the molecular mech-
anism through which fumagillin inhibits angiogenesis remains
to be elucidated [14,15].
In this study, we have established a screening system to iso-
late Vpr inhibitors. Using the system, we puriﬁed a Vpr
inhibitory compound from fungal metabolites and identiﬁed
it fumagillin. Fumagillin actually inhibited the HIV-1 infec-
tion of human macrophages. Our results demonstrate that
fumagillin can be a lead compound for the development of
the novel type of AIDS therapeutic drug that targets Vpr
activity.2. Materials and methods
2.1. Plasmids
For the expression of Vpr in yeast, XhoI–NotI fragments [16] of N-
terminal FLAG-tagged HIV-1NL4-3Vpr were blunted and inserted into
BamHI sites of copper inducible yeast expression vector, pYEX-BX
(AMRAD BIOTECH, Vic., Australia). Plasmids, in which FLAG-
Vpr transcription is driven in the reverse orientation under CUP1 pro-
moter, were used as control plasmids. For the introduction of these
plasmids into URA3 cells, the URA3 marker in pYEX-BX was chan-
ged to HIS3.2.2. Yeast strains, culture and Vpr inhibitor screening
A multidrug sensitive yeast strain (MLC30) and MetAP2 deletion
mutant strain (Dmap2, map2::URA3) were obtained from Dr. Tokichi
Miyakawa (Hiroshima Univ., Higashi-Hiroshima, Japan) and Dr.
Yie-Hwa Chang (St. Louis Univ. Sch. Med., MO), respectively
[17,18]. For expression of Vpr, yeast cells were cultured in the SD med-
ium (0.7% yeast nitrogen base (DIFCO), 2% glucose) containing amino
acids minus selective amino acids and 0.5 mM CuSO4. To silence the
expression, CuSO4 was removed and leucine was added to the culture.
For the screening of Vpr inhibitor on agar plates, MLC30 cells with Vpr
expression plasmids were cultured to log phase in the expression silenc-
ing media at 30 C, washed, suspended in expression inducing medium
at OD600 = 0.5 and cultured for an additional 30 min. Then, the culture
was mixed with 9 volumes of expression inducing medium containing
2% agar (Phytagar, GIBCO) and 0.001% SDS, poured into plasticblished by Elsevier B.V. All rights reserved.
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taining extracts of the culture broth to be tested were put on the plates
and the plates were incubated at 30 C for several days.
2.3. Puriﬁcation of fumagillin from a producing fungal strain
Fumagillin was isolated from the culture broth of a producing fun-
gal strain using bioassay-guided puriﬁcation procedures. The structure
of fumagillin was determined by the physico-chemical properties, de-
tailed 1H and 13C NMR analysis, and mass spectroscopy [19].
2.4. Synthesis of TNP470 and biotinylated fumagillin
TNP470 was synthesized from fumagillin as described previously
[20]. Biotinylated fumagillin was synthesized by a coupling reaction
via the carboxyl group of fumagillin using an activated biotin reagent
(Pierce). The structures of TNP470 and biotinylated fumagillin were
determined by their physico-chemical properties, detailed 1H and 13C
NMR analysis, and mass spectroscopies. Biotinylated fumagillin was
conﬁrmed to be eﬀective in MT-Vpr1 cells although it was weaker than
the original.
2.5. Human cell culture and immunological techniques
Cell culture, synchronization and FACS analysis of MT-Vpr1 cells,
a HeLa derived cell line with zinc inducible Vpr expression plasmids,
and immunological detection of Vpr in the cells were as described
[16]. Human embryonic kidney (HEK) 293 cells expressing SV40 large
T antigen (293T) were propagated in DMEM medium supplemented
with 10% FCS. Human primary monocytes and diﬀerentiated macro-
phages were obtained from peripheral blood mononuclear cells of
healthy donors as described [21].
2.6. Preparation of viruses
To generate the single-round replication incompetent luciferase re-
porter virus stocks (NL-Luc-ER+ or NL-Luc-ER)[2], 293T cells
were co-transfected with the proviral DNAs (obtained from Dr.
Nathaniel Landau through the AIDS Research and Reference Reagent
Program) and plasmids encoding vesicular stomatitis virus envelope
protein (pCMV-VSV-G-RSV-Rev). Culture supernatants were har-
vested at 60 h after the transfection and titrated.
2.7. Infectivity assays
Primary macrophages in 24 well plates were inoculated with VSV-G
pseudotyped reporter viruses (NL-Luc-ER+(VSV-G) or NL-Luc-
ER(VSV-G); 1.5 ng of p24gag antigen), cultured in the absence or
presence of the drug (fumagillin or TNP470) for 6 days, harvested,
lysed in luciferase assay substrate (Promega) and assayed for luciferase
activities using Wallac ARVO SX 1420 (Perkin–Elmer).Fig. 1. Screening system to isolate Vpr inhibitors. (A) Schematic presentati
embedded in agar plates containing inducer (copper). Paper ﬁlters with brot
surrounding ﬁlters that contain Vpr inhibitors were able to grow. (B,C) Gr
culture broth of a fungus with Vpr inhibitory activity (B) or puriﬁed fumagi
Chemical structures of fumagillin and TNP470.3. Results and discussion
3.1. Isolation of Vpr inhibitors using budding yeast cells
To isolate small molecules that inhibit the activity of Vpr, we
have established a screening system using budding yeast cells
expressing Vpr. As shown in Fig. 1A, yeast cells with cop-
per-inducible Vpr expression plasmids [22] were embedded in
agar plates containing the inducer (CuSO4). Then, paper ﬁlters
containing extracts of broth from cultured microorganisms
(fungi, actinomycetes or bacteria) were put on agar plates,
and the plates were incubated at 30 C for several days. Since
Vpr strongly inhibits the growth of yeast cells [22], no signiﬁ-
cant growth was usually detected even after 4–5 days of incu-
bation. However, very occasionally, signiﬁcant growth could
be detected surrounding the paper ﬁlters, indicating that the
culture broth extracts on the ﬁlters have an activity that antag-
onizes the action of Vpr (Fig. 1B). As a result of our extensive
screening program, we have puriﬁed the active compound and
identiﬁed it as fumagillin (Fig. 1C and D), a compound known
to be a potent inhibitor of angiogenesis [11]. Commercially
available fumagillin (Sigma) had speciﬁc activity similar to that
of our puriﬁed compound (not shown). The activity of fum-
agillin could also be detected when a galactose inducible sys-
tem was used for Vpr expression (not shown), suggesting
that this compound reverses the action of Vpr itself rather than
the expression of Vpr by copper inducible system (see below).3.2. Eﬀect of fumagillin and TNP470 on Vpr induced cell cycle
arrest in HeLa cells
Next, we examined the ability of fumagillin to antagonize
Vpr function in human cells. As described above, one of the
characteristic functions of Vpr in human cells is induction of
the cell cycle arrest at G2 phase [23,24]. We previously estab-
lished a HeLa derived cell line (MT-Vpr1) stably transfected
with a zinc-inducible Vpr expression vector [16]. In this cell
line, induction of Vpr expression arrests cell cycle at G2 phase
in more than half of the total cells a day after addition of the
inducer (Fig. 2A, Zn). When fumagillin (10 ng/ml) was added
before the addition of zinc, the G2 arrested population wason of Vpr screening system. Budding yeast cells expressing Vpr were
hs or compounds to be tested were put on the plates. Only the yeasts
owing yeasts surrounding ﬁlters containing 10 ll of extract from the
llin (C; 2 mg/ml, 10 ll). Plates were incubated for 4 days at 30 C. (D)
Fig. 2. Fumagillin and TNP470 inhibit Vpr activity in HeLa cells. (A)
Thirty minutes before the addition of zinc, fumagillin (FM) or TNP470
was added to MT-Vpr1 cells at the concentrations described. Cells
were cultured for a day in the presence or absence of zinc (Zn; 150 lM)
and harvested for FACS analysis. Numbers in the ﬁgures represent the
percentage of cells with 4C DNA contents. (B) Mt-Vpr1 cells were
synchronized at G1/S border [16], then released in the presence or
absence of zinc (Zn; 150 lM) and/or fumagillin (FM; 10 ng/ml). Zinc
and fumagillin were added at 2 and 1 h before the release, respectively.
Numbers in the ﬁgures represent the percentage of cells with 4C DNA
contents. (C) Cells as in (A) were cultured for 6 h and harvested for
western analysis to detect FLAG-Vpr expression [16]. Drugs were
added at 10 ng/ml.
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partially inhibit the action of Vpr in mammalian cells as well.
The eﬀect of higher doses (100 ng/ml and 1 lg/ml) of fumagil-
lin on the action of Vpr was almost similar to that at 10 ng/ml
in this system (not shown).
A synthetic analog of fumagillin, TNP470 (AGM-1470;
Fig. 1D) is a more potent angiogenesis inhibitor [11]. However,
the ability of TNP470 to antagonize Vpr function was similar
to or less than that of fumagillin (Fig. 2A, Zn + TNP470).
Thus, fumagillin seems to override Vpr-dependent cell cycle ar-
rest in a manner diﬀerent from that through which it blocks
angiogenesis.
In this system, however, if fumagillin has an activity to arrest
cell cycle at a phase other than G2 phase, an apparent reduc-
tion of G2 arrested cells would be observed. To examine this
possibility, the eﬀect of fumagillin on cell cycle progression
was examined. After MT-Vpr1 cells were synchronized atG1/S border and released in the presence or absence of fum-
agillin, progression through S, G2, M and G1 was monitored
by FACS analysis (Fig. 2B). In the absence of zinc, cell cycle
progression was not aﬀected by fumagillin (None and FM).
When Vpr expression was induced by zinc addition, a similar
fraction of cells was arrested at G2 at 12 h after the release
regardless of the presence of fumagillin. But, in the presence
of fumagillin, the fraction of cells arrested at G2 phase was sig-
niﬁcantly reduced at later time points (Zn and Zn + FM).
These results indicate that fumagillin does not aﬀect normal
cell cycle progression but reduces the activity of Vpr to arrest
the cell cycle. We have also conﬁrmed that neither fumagillin
nor TNP470 has any eﬀect on the zinc induced Vpr expression
level in MT-Vpr1 cells (Fig. 2C).
3.3. Vpr inhibits growth of yeast cells independently from
MetAP2 pathway
Fumagillin is known to covalently bind and inhibit a prote-
ase, MetAP2 both in human and budding yeast cells [12,13].
However, since there are two reports contradicting each other
about the matter whether inhibition of angiogenesis by fum-
agillin is dependent on the MetAP2 activity or not, the molec-
ular mechanism through which fumagillin inhibits
angiogenesis remains to be elucidated [14,15].
We examined whether MetAP2 is on the pathway for Vpr-
dependent growth arrest and whether fumagillin blocks the
activity of Vpr through the inhibition of MetAP2 or not. In
budding yeast, the gene (MAP2) that encodes MetAP2 is not
essential, because there is a second aminopeptidase, MetAP1,
which is insensitive to fumagillin [12,13,18]. Vpr arrested the
growth of Dmap2 strain cells almost as completely as wild type,
indicating that MetAP2 is not on the pathway of the Vpr
dependent growth arrest (Fig. 3A). The ability of fumagillin
to reverse the Vpr dependent arrest in Dmap2 strain cells was
conﬁrmed on paper disk assay as well (data not shown). These
results indicate that fumagillin abrogates Vpr function by tar-
geting (a) molecule(s) other than MetAP2. Since the sensitivity
to fumagillin and TNP470 is diﬀerent for Vpr-dependent arrest
and inhibition of angiogenesis, the target molecule(s) for these
drugs may be diﬀerent in these two systems.
3.4. Mechanism of fumagillin to inhibit Vpr function
Using biotinylated fumagillin, we attempted to detect any
covalent or strong binding between Vpr and fumagillin. Biotin-
ylated fumagillin was added to the lysates of MT-Vpr1 cells or
yeast cells expressing FLAG-tagged Vpr. After the lysates were
separated on SDS–PAGE and transferred on membrane, pro-
teins covalently bound to fumagillin such as MetAP2 were
probed with horse radish peroxidase (HRP) labelled streptavi-
din. Alternatively, proteins associated with biotinylated fum-
agillin were isolated using streptavidin conjugated agarose
beads, and probed with aFLAG antibody to detect FLAG
tagged Vpr. In spite of all of these attempts, we were unable
to obtain any evidence for the interaction between Vpr and
fumagillin (not shown). However, when point-mutations
(Q3R, E25K, A30L, W54A, L64A, H71R, R73A, I74R,
G75A, C76A, R80A, and R90K) were introduced into Vpr
and their sensitivity to fumagillin was examined on paper disk
assay, we found that the E25K mutation (the 25th glutamate
of Vpr was changed to lysine) makes Vpr signiﬁcantly resistant
to fumagillin (Fig. 3B). Since the E25K Vpr still inhibits
growth of yeast cells [25], the mechanism of fumagillin may
Fig. 3. Mechanism of fumagillin to abrogate the Vpr activity. (A) Vpr
inhibits growth of yeast cells independently from MetAP2 activity.
Dmap2 cells (right) or its isogenic control cells (left) were cultured in
the presence (closed circle) or absence (open circle) of the Vpr
expression. The growth of yeast cells was monitored with the
absorbance at 600 nm. (B) E25K mutation makes Vpr resistant to
fumagillin. Yeast cells with wild type Vpr (left) or E25K mutated Vpr
were embedded in agar plates as in Fig. 1. Paper ﬁlters with 20 lg of
fumagillin were put on the plates and incubated for 3 days at 30 C.
Photographs were taken with translucent light to increase sensitivity.
Fig. 4. Fumagillin and TNP470 inhibit Vpr dependent proviral gene
expression. (A,B) Macrophages were infected with HIV-1 reporter
vector with wild type (closed circle) or truncated (open circle) Vpr and
cultured in the presence of fumagillin (A) or TNP470 (B). The proviral
gene expression was monitored by the luciferase activity 6 days after
the infection using luciferase assay substrate (Promega).
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precise mechanism through which the E25K mutation renders
Vpr resistant to fumagillin is not clear, but it is possible that
fumagillin interacts directly (albeit too weakly to detect) with
Vpr at residues surrounding E25.
3.5. Inhibition of Vpr-dependent viral gene expression by
fumagillin or TNP470
Vpr is required for eﬃcient replication of HIV-1 in non-
dividing cells such as macrophages [2–4]. During the HIV-1 life
cycle, Vpr functions after entry and reverse transcription, yet
prior to, or at the time of, proviral transcription [2]. Thus we
examined the eﬀect of fumagillin on the proviral transcription
upon the infection using an env-deﬁcient HIV-1 vector that al-
lows only a single round of infection. Wild type or frame-
shifted Vpr-containing, env-deﬁcient HIV-1 reporter vector in
which Nef has been replaced by the luciferase gene (NL-Luc-
R+ or NL-Luc-R, respectively) [2] was used to infect primary
human macrophages (Fig. 4A and B). Luciferase activity,
determined 6 days after infection, was about 4 times higher
from the Vpr+ virus than that from the Vpr virus, indicating
that Vpr is required for eﬃcient expression of virally encoded
genes in macrophages [2]. When fumagillin or TNP470 was
added at the time of infection, luciferase expression from the
Vpr+ virus but not from the Vpr virus was inhibited in a
dose-dependent manner. Under these experimental condition,we could not see any sign of toxicity of 1 lg/ml of fumagillin
for the macrophages under microscope indicating that the inhi-
bition of viral gene expression in Vpr+ infected cells is due to
the inhibition of Vpr by these drugs rather than to some
non-speciﬁc toxicity of them. Taken together, our results show
that fumagillin or TNP470 suppresses the HIV-1 replication in
macrophages through inhibition of Vpr-dependent viral gene
expression.
3.6. Concluding remarks
Because it is now evident that Vpr’s contribution to the
pathogenesis of HIV-1 infection in vivo is crucial, Vpr has
been proposed to be an attractive target for developing novel
therapeutic strategies for AIDS therapy. Our results show that
fumagillin and its derivatives can be used as a new type of
AIDS therapeutic drug, which targets Vpr. In this context, it
should be noted that fumagillin and TNP470 are already used
clinically to treat Kaposi’s sarcoma or microsporidiosis in
AIDS patients with successful results [26,27], although the ef-
fects of these drugs on the viral replication have not been re-
ported. Thus, the day when the fumagillin-derived
compounds can be used clinically to prevent HIV-1 replication
may come sooner than expected.
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